AU2021293780A1 - Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery - Google Patents

Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery Download PDF

Info

Publication number
AU2021293780A1
AU2021293780A1 AU2021293780A AU2021293780A AU2021293780A1 AU 2021293780 A1 AU2021293780 A1 AU 2021293780A1 AU 2021293780 A AU2021293780 A AU 2021293780A AU 2021293780 A AU2021293780 A AU 2021293780A AU 2021293780 A1 AU2021293780 A1 AU 2021293780A1
Authority
AU
Australia
Prior art keywords
polymer
amine
substituted
pace
polyplexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021293780A
Other languages
English (en)
Inventor
Molly GRUN
Yuhang JIANG
W. Mark Saltzman
Alexandra SUBERI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2021293780A1 publication Critical patent/AU2021293780A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/60—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from the reaction of a mixture of hydroxy carboxylic acids, polycarboxylic acids and polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6854—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/6856—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C08G63/914—Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/916—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Polyesters Or Polycarbonates (AREA)
AU2021293780A 2020-06-19 2021-05-27 Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery Pending AU2021293780A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063041739P 2020-06-19 2020-06-19
US63/041,739 2020-06-19
PCT/US2021/034462 WO2021257262A1 (en) 2020-06-19 2021-05-27 Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery

Publications (1)

Publication Number Publication Date
AU2021293780A1 true AU2021293780A1 (en) 2023-02-02

Family

ID=76859713

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021293780A Pending AU2021293780A1 (en) 2020-06-19 2021-05-27 Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery

Country Status (10)

Country Link
US (1) US12558429B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168471A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023531444A (cg-RX-API-DMAC7.html)
KR (1) KR20230042018A (cg-RX-API-DMAC7.html)
CN (1) CN116157444A (cg-RX-API-DMAC7.html)
AU (1) AU2021293780A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025855A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183351A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016581A (cg-RX-API-DMAC7.html)
WO (1) WO2021257262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
CA3183351A1 (en) 2020-06-19 2021-12-23 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
WO2023108076A1 (en) * 2021-12-08 2023-06-15 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
US20250154317A1 (en) * 2022-02-18 2025-05-15 Yale University Branched poly(amine-co-ester) polymers for more efficient nucleic expression
CN114874422B (zh) * 2022-06-16 2023-05-12 上海云沂生物医药科技有限公司 一种聚烷基胺、其合成方法、颗粒及用途
EP4324485A1 (en) * 2022-08-15 2024-02-21 Branca Banus Ltd A method for the production of pegylated hyperbranched poly( -amino ester)s, pegylated hyperbranched poly( -amino ester)s produced by those methods and their use in enhanced nucleic acid delivery
WO2024103225A1 (zh) * 2022-11-14 2024-05-23 林桂孜 一种阳离子聚酯及其制备方法和应用
EP4725977A1 (en) * 2023-06-08 2026-04-15 Integena Inc Efficient cationic polyester and use thereof
CN119490670A (zh) * 2024-11-26 2025-02-21 山东大学 一种慢病毒转染增强纳米颗粒及其制备方法与应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415728A (en) 1979-11-08 1983-11-15 Her Majesty The Queen In Right Of Canada ε-Caprolactone co-polyesters useful for the preparation of polyurethane
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン,ジエ−ムス ポリヌクレオチド測定試薬と方法
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6849272B1 (en) 1999-04-21 2005-02-01 Massachusetts Institute Of Technology Endosomolytic agents and cell delivery systems
MXPA03000905A (es) 2000-08-02 2003-06-24 Slil Biomedical Corp Compuestos de poliamina ciclicos como tratamiento contra el cancer.
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20030008000A1 (en) 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
CN1764464A (zh) 2003-02-14 2006-04-26 英诺莱克斯投资股份有限公司 叔胺基官能团复合聚酯聚合物及其制备方法和应用
KR100498971B1 (ko) 2003-04-04 2005-07-04 씨제이 주식회사 염색체 내 tdcBC 및 pckA 유전자가 불활성화된 미생물 및 이를 이용하여 L-쓰레오닌을 제조하는 방법
US20040242831A1 (en) 2003-05-30 2004-12-02 Dong Tian Enzyme catalyzed polyesters and polyol polymers
FR2873570B1 (fr) 2004-08-02 2007-01-05 Oreal Composition cosmetique de soin et/ou de maquillage comprenant au moins un polymere polyester amide
US8124128B2 (en) 2005-11-08 2012-02-28 Industrial Technology Research Institute Amphiphilic block copolymers and nano particles comprising the same
US20090018216A1 (en) * 2006-03-01 2009-01-15 The University Of Tokyo Polymer micelle complex including nucleic acid
US9241898B2 (en) 2008-03-11 2016-01-26 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9272043B2 (en) 2011-12-02 2016-03-01 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
US10682422B2 (en) 2014-11-18 2020-06-16 Yale University Formulations for targeted release of agents under low pH conditions and methods of use thereof
WO2017151623A1 (en) * 2016-03-01 2017-09-08 Alexion Pharmaceuticals, Inc. Biodegradable activated polymers for therapeutic delivery
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US10874737B2 (en) 2018-06-01 2020-12-29 Iowa State University Research Foundation, Inc. Influenza nanovaccine
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US12162953B2 (en) 2019-12-06 2024-12-10 Yale University Enhanced targeting platform
DE202021004130U1 (de) 2020-02-04 2022-10-26 Curevac Ag Coronavirus-Vakzine
BR112022015666A2 (pt) 2020-02-14 2022-09-27 Etherna Immunotherapies Nv Vacinas intranasais de mrna
CA3183351A1 (en) 2020-06-19 2021-12-23 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
US20220031633A1 (en) 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
US20240342271A1 (en) 2021-08-03 2024-10-17 Bharat Biotech International Limited Synergism of immunogenicity via combined parenteral and mucosal immunization against covid-19
WO2023108076A1 (en) 2021-12-08 2023-06-15 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues

Also Published As

Publication number Publication date
BR112022025855A2 (pt) 2023-01-10
JP2023531444A (ja) 2023-07-24
US12558429B2 (en) 2026-02-24
US20230233693A1 (en) 2023-07-27
JP2026003134A (ja) 2026-01-09
WO2021257262A1 (en) 2021-12-23
EP4168471A1 (en) 2023-04-26
MX2022016581A (es) 2023-02-01
CA3183351A1 (en) 2021-12-23
KR20230042018A (ko) 2023-03-27
CN116157444A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
US12030985B2 (en) Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US12558429B2 (en) Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
US9895451B2 (en) Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
US9567430B2 (en) Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US10465042B2 (en) Poly(amine-co-ester) nanoparticles and methods of use thereof
WO2013082529A1 (en) Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US10682422B2 (en) Formulations for targeted release of agents under low pH conditions and methods of use thereof
Convertine et al. pH-responsive polymeric micelle carriers for siRNA drugs
Liang et al. Self-assembled ternary complexes stabilized with hyaluronic acid-green tea catechin conjugates for targeted gene delivery
Liu et al. Development of delivery strategies for CRISPR‐Cas9 genome editing
WO2016081621A1 (en) Formulations for targeted release of agents under low ph conditions and methods of use thereof
WO2017197128A1 (en) Poly(amine-co-ester) nanoparticles and methods of use thereof
EP3423106B1 (en) Biodegradable activated polymers for therapeutic delivery
US20250241865A1 (en) Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
Laomeephol et al. Potential roles of hyaluronic acid in in vivo CAR T cell reprogramming for cancer immunotherapy
Zhang et al. A zwitterionic polymer-inspired material mediated efficient CRISPR-Cas9 gene editing
Chen et al. Polyethyleneimine-grafted poly (N-3-hydroxypropyl) aspartamide as a biodegradable gene vector for efficient gene transfection
US20250154317A1 (en) Branched poly(amine-co-ester) polymers for more efficient nucleic expression
WO2025101580A1 (en) Half-antibodies and other antibody fragments for attachment to degradable polymer nanoparticles
Wang Multifunctional Nanoplatforms for the Delivery of CRISPR/Cas9-Based Genome Editing Machinery
Hetti Development of novel biodegradable core-shell nanoparticles as carriers for gene delivery
Liu Photo-assisted gene therapy using light-responsive catanionic vesicles
Asthana et al. Research Article Mannosylated Chitosan Nanoparticles for Delivery of Antisense Oligonucleotides for Macrophage Targeting